What are we looking for?
Ferring's primary business development objective is to complement the company's portfolio. A key strategic objective is to grow our business in the United States and Japan. In particular, the company is interested in late-stage products (phase IIb and onwards), as well as products already marketed globally and regionally.
Areas of interest
- Over the next few years Ferring will be looking for products to supplement PENTASA® and its R&D gastro pipeline for the treatment of Crohn's disease and ulcerative colitis.
- Long term, Ferring is interested in new treatment options for inflammatory bowel diseases and other lower gastro-intestinal conditions.
- Long term, Ferring is looking to develop the next generation of the GLYPRESSIN®-inspired treatments.
Ferring Pharmaceuticals is committed to obstetrics and gynaecology where its existing products concentrate on utilising the body's natural processes to help couples conceive and to ensure a successful pregnancy.
By being able to offer new and innovative products in these areas, it is Ferring's vision to provide the best treatments to aid every stage of the reproductive cycle.
Furthermore Ferring aims to help women to overcome and live with diseases of the Reproductive System.
Ferring is interested in innovative products to supplement its existing portfolio of drugs in the Urology and Uro-Oncology area.
We are also receptive to considering opportunities targeting specialty physician segments which may be outside of our core therapeutic areas.
Ferring's business development activities have led to a variety of mergers, acquisitions, license arrangements, and development collaborations with companies around the world, including transactions with the following companies (please click on the links to view the related press releases):
Preclinical Research Programmes
The Senior Director of Business Development for the Ferring Research Institute is responsible for reviewing peptide and protein-based preclinical research programmes and technologies that have potential utility in Ferring’s core therapeutic areas.
Senior Director, Business Development Research
Phone: +1 858 657 1511 (USA)
email: adrienne.day at ferring dot com
R&D Innovation Sourcing
Ferring's Senior Vice President, Global Project and Portfolio Management, leads the evaluation of R&D opportunities in pre-phase IIB development and consults with other relevant Ferring divisions. In addition, he leads the out-licensing process of Ferring's early-stage compounds.
Early Stage Clinical Compounds and Drug Delivery Systems
Alan S. Harris
Senior Vice President, Global Project and Portfolio Management Phone: +41 58 301 00 00 (Switzerland) email: firstname.lastname@example.org
Business Development Manager, Early Stage Portfolio Phone: +41 58 451 40 73 (Switzerland) email: Casper.email@example.com
Director, R&D Innovation Phone: +1 858 657 1548 (USA) email: Geoffrey.Harris@ferring.com
Director, R&D Innovation Phone: +45 88 18 71 50 (Denmark) email: Morten.Persson@ferring.com
Director, R&D Innovation Phone: +86 21 80 303 090 (China) email: DONGHUI.QIN@ferring.com
Robert Woolley Manager, Innovation & Development Phone: +55 113 024 75 78 (Brazil) email: Robert.Woolley@ferring.com
Late Stage and Merger & Acquisitions
Ferring's Business Development team focuses on late stage compounds that are ready to go to phase III as well as on product and company acquisitions.
Reproductive Health, New Therapeutic Areas and/or Europe
Senior Vice President, Global Operations Management
Phone: +41 58 301 00 00 (Switzerland) email: firstname.lastname@example.org
Gastro, Endocrinology, Urology and/or Asia, Middle East, Latin America
Senior Director, Global Business Development
Phone: +41 58 301 00 00 (Switzerland)